Protalix BioTherapeutics (PLX) Long-Term Deferred Tax (2018 - 2026)

Protalix BioTherapeutics has reported Long-Term Deferred Tax for 5 years, with the latest figure at $2.4 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Deferred Tax fell 17.65% year-over-year to $2.4 million; the trailing twelve-month figure through Mar 2026 stood at $2.4 million (down 17.65% YoY), and the FY2025 full-year result was $2.5 million, down 11.9% from the prior year.
• Long-Term Deferred Tax for Q1 2026 stood at $2.4 million, down from $2.5 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $3.3 million in Q2 2024, with the low at $2.4 million in Q1 2026.
• Average Long-Term Deferred Tax over 4 years is $2.9 million, with a median of $2.9 million recorded in 2024.
• Year-over-year, Long-Term Deferred Tax grew 5.4% in 2024 and retreated 17.65% in 2026.
• Tracing PLX's Long-Term Deferred Tax over 4 years: stood at $3.1 million in 2023, then declined by 7.63% to $2.9 million in 2024, then decreased by 11.9% to $2.5 million in 2025, then decreased by 2.82% to $2.4 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $2.4 million (Q1 2026), $2.5 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.

Peer Comparison